nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftizoxime—Injection site burning—Carmustine—lymphatic system cancer	0.1	0.1	CcSEcCtD
Ceftizoxime—Nephropathy toxic—Teniposide—lymphatic system cancer	0.0292	0.0292	CcSEcCtD
Ceftizoxime—Induration—Bleomycin—lymphatic system cancer	0.0242	0.0242	CcSEcCtD
Ceftizoxime—Nephropathy toxic—Bleomycin—lymphatic system cancer	0.0188	0.0188	CcSEcCtD
Ceftizoxime—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.0183	0.0183	CcSEcCtD
Ceftizoxime—Numbness—Fludarabine—lymphatic system cancer	0.0178	0.0178	CcSEcCtD
Ceftizoxime—Sensory loss—Fludarabine—lymphatic system cancer	0.017	0.017	CcSEcCtD
Ceftizoxime—Nephropathy toxic—Carmustine—lymphatic system cancer	0.0164	0.0164	CcSEcCtD
Ceftizoxime—Nephropathy toxic—Mitoxantrone—lymphatic system cancer	0.0153	0.0153	CcSEcCtD
Ceftizoxime—Phlebitis—Teniposide—lymphatic system cancer	0.0141	0.0141	CcSEcCtD
Ceftizoxime—Pancytopenia—Mechlorethamine—lymphatic system cancer	0.0136	0.0136	CcSEcCtD
Ceftizoxime—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.0135	0.0135	CcSEcCtD
Ceftizoxime—Phlebitis—Fludarabine—lymphatic system cancer	0.0124	0.0124	CcSEcCtD
Ceftizoxime—Tenderness—Bleomycin—lymphatic system cancer	0.0124	0.0124	CcSEcCtD
Ceftizoxime—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.0119	0.0119	CcSEcCtD
Ceftizoxime—Injection site pain—Carmustine—lymphatic system cancer	0.0116	0.0116	CcSEcCtD
Ceftizoxime—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.0115	0.0115	CcSEcCtD
Ceftizoxime—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.0114	0.0114	CcSEcCtD
Ceftizoxime—Numbness—Vincristine—lymphatic system cancer	0.0109	0.0109	CcSEcCtD
Ceftizoxime—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Ceftizoxime—Sensory loss—Vincristine—lymphatic system cancer	0.0104	0.0104	CcSEcCtD
Ceftizoxime—Pancytopenia—Teniposide—lymphatic system cancer	0.01	0.01	CcSEcCtD
Ceftizoxime—Neutropenia—Teniposide—lymphatic system cancer	0.00985	0.00985	CcSEcCtD
Ceftizoxime—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00965	0.00965	CcSEcCtD
Ceftizoxime—Phlebitis—Bleomycin—lymphatic system cancer	0.00912	0.00912	CcSEcCtD
Ceftizoxime—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00891	0.00891	CcSEcCtD
Ceftizoxime—Pancytopenia—Fludarabine—lymphatic system cancer	0.00879	0.00879	CcSEcCtD
Ceftizoxime—Neutropenia—Fludarabine—lymphatic system cancer	0.00866	0.00866	CcSEcCtD
Ceftizoxime—Haemoglobin—Teniposide—lymphatic system cancer	0.00847	0.00847	CcSEcCtD
Ceftizoxime—Haemorrhage—Teniposide—lymphatic system cancer	0.00843	0.00843	CcSEcCtD
Ceftizoxime—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00818	0.00818	CcSEcCtD
Ceftizoxime—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00812	0.00812	CcSEcCtD
Ceftizoxime—Phlebitis—Carmustine—lymphatic system cancer	0.00796	0.00796	CcSEcCtD
Ceftizoxime—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00796	0.00796	CcSEcCtD
Ceftizoxime—Haemoglobin—Fludarabine—lymphatic system cancer	0.00745	0.00745	CcSEcCtD
Ceftizoxime—Haemorrhage—Fludarabine—lymphatic system cancer	0.00741	0.00741	CcSEcCtD
Ceftizoxime—Phlebitis—Mitoxantrone—lymphatic system cancer	0.0074	0.0074	CcSEcCtD
Ceftizoxime—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00737	0.00737	CcSEcCtD
Ceftizoxime—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00701	0.00701	CcSEcCtD
Ceftizoxime—Anaemia—Teniposide—lymphatic system cancer	0.00678	0.00678	CcSEcCtD
Ceftizoxime—Leukopenia—Teniposide—lymphatic system cancer	0.00657	0.00657	CcSEcCtD
Ceftizoxime—Pancytopenia—Bleomycin—lymphatic system cancer	0.00645	0.00645	CcSEcCtD
Ceftizoxime—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00599	0.00599	CcSEcCtD
Ceftizoxime—Anaemia—Fludarabine—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Ceftizoxime—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00586	0.00586	CcSEcCtD
Ceftizoxime—Leukopenia—Fludarabine—lymphatic system cancer	0.00577	0.00577	CcSEcCtD
Ceftizoxime—Pruritus—Mechlorethamine—lymphatic system cancer	0.00575	0.00575	CcSEcCtD
Ceftizoxime—Pancytopenia—Carmustine—lymphatic system cancer	0.00563	0.00563	CcSEcCtD
Ceftizoxime—Convulsion—Fludarabine—lymphatic system cancer	0.00559	0.00559	CcSEcCtD
Ceftizoxime—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00556	0.00556	CcSEcCtD
Ceftizoxime—Neutropenia—Carmustine—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Ceftizoxime—Haemoglobin—Bleomycin—lymphatic system cancer	0.00546	0.00546	CcSEcCtD
Ceftizoxime—Haemorrhage—Bleomycin—lymphatic system cancer	0.00543	0.00543	CcSEcCtD
Ceftizoxime—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00541	0.00541	CcSEcCtD
Ceftizoxime—Pancytopenia—Vincristine—lymphatic system cancer	0.00537	0.00537	CcSEcCtD
Ceftizoxime—Neutropenia—Vincristine—lymphatic system cancer	0.00529	0.00529	CcSEcCtD
Ceftizoxime—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00526	0.00526	CcSEcCtD
Ceftizoxime—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.00523	0.00523	CcSEcCtD
Ceftizoxime—Vomiting—Mechlorethamine—lymphatic system cancer	0.00517	0.00517	CcSEcCtD
Ceftizoxime—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00515	0.00515	CcSEcCtD
Ceftizoxime—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00515	0.00515	CcSEcCtD
Ceftizoxime—Rash—Mechlorethamine—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Ceftizoxime—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Ceftizoxime—Nausea—Mechlorethamine—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Ceftizoxime—Haemoglobin—Carmustine—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Ceftizoxime—Haemorrhage—Carmustine—lymphatic system cancer	0.00474	0.00474	CcSEcCtD
Ceftizoxime—Body temperature increased—Teniposide—lymphatic system cancer	0.00474	0.00474	CcSEcCtD
Ceftizoxime—Paraesthesia—Fludarabine—lymphatic system cancer	0.00473	0.00473	CcSEcCtD
Ceftizoxime—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00472	0.00472	CcSEcCtD
Ceftizoxime—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00458	0.00458	CcSEcCtD
Ceftizoxime—Hypoaesthesia—Vincristine—lymphatic system cancer	0.0045	0.0045	CcSEcCtD
Ceftizoxime—Pain—Fludarabine—lymphatic system cancer	0.0045	0.0045	CcSEcCtD
Ceftizoxime—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Ceftizoxime—Hypersensitivity—Teniposide—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Ceftizoxime—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Ceftizoxime—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Ceftizoxime—Anaemia—Bleomycin—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Ceftizoxime—Pruritus—Teniposide—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Ceftizoxime—Leukopenia—Bleomycin—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Ceftizoxime—Body temperature increased—Fludarabine—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Ceftizoxime—Vaginal infection—Methotrexate—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Ceftizoxime—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Ceftizoxime—Diarrhoea—Teniposide—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Ceftizoxime—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Ceftizoxime—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Ceftizoxime—Anaemia—Carmustine—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Ceftizoxime—Vomiting—Teniposide—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Ceftizoxime—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Ceftizoxime—Rash—Teniposide—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Ceftizoxime—Dermatitis—Teniposide—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Ceftizoxime—Pruritus—Fludarabine—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Ceftizoxime—Leukopenia—Carmustine—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Ceftizoxime—Anaemia—Vincristine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Ceftizoxime—Diarrhoea—Fludarabine—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Ceftizoxime—Convulsion—Carmustine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Ceftizoxime—Nausea—Teniposide—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Ceftizoxime—Anaemia—Mitoxantrone—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Ceftizoxime—Leukopenia—Vincristine—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Ceftizoxime—Paraesthesia—Bleomycin—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Ceftizoxime—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Ceftizoxime—Convulsion—Vincristine—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Ceftizoxime—Vomiting—Fludarabine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Ceftizoxime—Convulsion—Mitoxantrone—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Ceftizoxime—Rash—Fludarabine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Ceftizoxime—Dermatitis—Fludarabine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Ceftizoxime—Pain—Bleomycin—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Ceftizoxime—Thrombocytopenia—Carmustine—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Ceftizoxime—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Ceftizoxime—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Ceftizoxime—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Ceftizoxime—Nausea—Fludarabine—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Ceftizoxime—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Ceftizoxime—Body temperature increased—Bleomycin—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Ceftizoxime—Paraesthesia—Carmustine—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Ceftizoxime—Paraesthesia—Vincristine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Ceftizoxime—Pain—Carmustine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Ceftizoxime—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Ceftizoxime—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Ceftizoxime—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Ceftizoxime—Pain—Vincristine—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Ceftizoxime—Pruritus—Bleomycin—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Ceftizoxime—Eosinophilia—Methotrexate—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Ceftizoxime—Pain—Mitoxantrone—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Ceftizoxime—Body temperature increased—Carmustine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Ceftizoxime—Pancytopenia—Methotrexate—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Ceftizoxime—Neutropenia—Methotrexate—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Ceftizoxime—Body temperature increased—Vincristine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Ceftizoxime—Hypersensitivity—Carmustine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Ceftizoxime—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Ceftizoxime—Vomiting—Bleomycin—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Ceftizoxime—Rash—Bleomycin—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Ceftizoxime—Dermatitis—Bleomycin—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Ceftizoxime—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Ceftizoxime—Hypersensitivity—Vincristine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Ceftizoxime—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Ceftizoxime—Diarrhoea—Carmustine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Ceftizoxime—Nausea—Bleomycin—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Ceftizoxime—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Ceftizoxime—Haemoglobin—Methotrexate—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Ceftizoxime—Diarrhoea—Vincristine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Ceftizoxime—Haemorrhage—Methotrexate—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Ceftizoxime—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Ceftizoxime—Vomiting—Carmustine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Ceftizoxime—Rash—Carmustine—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Ceftizoxime—Dermatitis—Carmustine—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Ceftizoxime—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Ceftizoxime—Vomiting—Vincristine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Ceftizoxime—Rash—Vincristine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Ceftizoxime—Dermatitis—Vincristine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Ceftizoxime—Nausea—Carmustine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Ceftizoxime—Vomiting—Mitoxantrone—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Ceftizoxime—Rash—Mitoxantrone—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Ceftizoxime—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Ceftizoxime—Nausea—Vincristine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Ceftizoxime—Nausea—Mitoxantrone—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Ceftizoxime—Anaemia—Methotrexate—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Ceftizoxime—Leukopenia—Methotrexate—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Ceftizoxime—Convulsion—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Ceftizoxime—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Ceftizoxime—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Ceftizoxime—Paraesthesia—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Ceftizoxime—Pain—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Ceftizoxime—Body temperature increased—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Ceftizoxime—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Ceftizoxime—Pruritus—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Ceftizoxime—Diarrhoea—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Ceftizoxime—Vomiting—Methotrexate—lymphatic system cancer	0.000992	0.000992	CcSEcCtD
Ceftizoxime—Rash—Methotrexate—lymphatic system cancer	0.000984	0.000984	CcSEcCtD
Ceftizoxime—Dermatitis—Methotrexate—lymphatic system cancer	0.000983	0.000983	CcSEcCtD
Ceftizoxime—Nausea—Methotrexate—lymphatic system cancer	0.000927	0.000927	CcSEcCtD
